Episode Details
Back to Episodes
AbbVie Eyes $11B Apogee Deal
Published 21 hours ago
Description
AbbVie’s rumored $11 billion bid for Apogee Therapeutics could reshape pharma—fueling excitement as AbbVie seeks to bolster its pipeline amid looming patent expirations, while Apogee’s promising compounds might finally get the resources to reach patients faster. Deal’s still pending, but this blockbuster move signals big pharma’s relentless push for innovation.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
advertise@thednn.ai
This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.
View sources & latest updates:
https://sources.thednn.ai/1a6689c71bb3366c